Barclays double downgraded Smith & Nephew to Underweight from Overweight with a price target of 1,100 GBp, down from 1,480 GBp. The analyst sees further share losses in orthopedics, which will push out the company’s turnaround.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SNN:
- Smith & Nephew price target raised to 1,600 GBp from 1,500 GBp at RBC Capital
- Smith & Nephew re-initiated with an Outperform at Bernstein
- Smith & Nephew upgraded to Buy from Hold at Liberum
- Smith & Nephew price target raised to 1,000 GBp from 970 GBp at UBS
- Smith & Nephew price target lowered to 1,480 GBp from 1,500 GBp at Barclays